NCT04136223View on ClinicalTrials.gov

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression

UnknownOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Rheumatoid LungRheumatoid ArthritisInterstitial Lung DiseasePulmonary Fibrosis
Trial Locations (5)

70840-901

Hospital Universitário de Brasilia (HUB), Brasília

05403-000

Hospital das Clinicas - FMUSP, São Paulo

Unknown

Universidade Estadual de Campinas (UNICAMP), Campinas

LABOX - Federal University of Santa Catarina (UFSC), Florianópolis

LAPOGE - Federal University of Santa Catarina (UFSC), Florianópolis

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Hospital do Coracao

OTHER

NCT04136223 - Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression | Biotech Hunter | Biotech Hunter